Summary
Thrombocytopenia absent radii (TAR) syndrome is clearly defined by the combination of radial aplasia and reduced platelet counts. The genetics of TAR syndrome has recently been resolved and comprises a microdeletion on Chromosome 1 including the RBM8A gene and a single nucleotide polymorphism (SNP) either at the 5 0 untranslated region (5 0 UTR) or within the first intron of RBM8A. Although phenotypically readily diagnosed after birth, the genetic determination of particular SNPs in TAR syndrome harbours valuable information to evaluate disease severity and treatment decisions. Here, we present clinical data in a cohort of 38 patients and observed that platelet counts in individuals with 5 0 UTR SNP are significantly lower compared to patients bearing the SNP in intron 1. Moreover, elevated haemoglobin values could only be assessed in patients with 5 0 UTR SNP whereas white blood cell count is unaffected, indicating that frequently observed anaemia in TAR patients could also be SNPdependent whereas leucocytosis does not correlate with genetic background. However, this report on a large cohort provides an overview of important haematological characteristics in TAR patients, facilitating evaluation of the various traits in this disease and indicating the importance of genetic validation for TAR syndrome.
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Thrombocytopenia absent radii (TAR) syndrome is a very rare congenital disorder with the key aspects of thrombocytopenia linked with bilateral radius aplasia by the presence of both thumbs (Hall et al, 1969) . Patients can have many additional features, including skeletal, urogenital and heart defects (Hedberg & Lipton, 1988; Greenhalgh et al, 2002; Geddis, 2009) . TAR has long remained a disorder for which neither a genetic nor a molecular basis has been identified. Recently, our group contributed to the discovery of two genetic modifications underlying the majority of all patients with TAR syndrome: the microdeletion on chromosome 1q21 (Klopocki et al, 2007) and the occurrence of one of two rare single nucleotide polymorphisms (SNPs) in noncoding regions of the RBM8A gene (Albers et al, 2012) . RBM8A is located within the microdeleted region on Chromosome 1q21 and encodes a protein designated Y14, a core subunit of the exon junction complex (Le Hir et al, 2001) . Although the association between both genetic alterations is extremely high, so far the underlying mechanisms for the isolated thrombocytopenia and for the bilateral radius aplasia are completely elusive.
Patients are typically born with very low platelet counts (often <30 9 10 9 /l) and might already harbour petechiae and other signs of bleeding. Several case reports additionally describe altered white cell counts, with leucocytosis and eosinophilia (Hall et al, 1969; Hedberg & Lipton, 1988) . During the first year of life children could potentially harbour anaemia, which cannot fully be attributed to increased incidence of bleedings. In most patients, platelet counts remain low during the first 2 years and then ameliorate up to approximately 100 9 10 9 /l. Therefore, they still do not reach the lower reference value . The exact mechanisms underlying this increase in platelets have remained enigmatic.
The low platelet count in TAR syndrome is a consequence of the paucity of megakaryocytes in the bone marrow, while other cell lineages are not affected (de Alarcon et al, 1991; Ballmaier et al, 1997) . TAR has sometimes been considered to be a member of the unilineage bone marrow failure syndromes (BMFS) (Shimamura & Alter, 2010) comparable to congenital amegakaryocytic thrombocytopenia (CAMT) (Ballmaier et al, 2001) . We and others have demonstrated that haematopoietic stem and progenitor cells residing in the bone marrow do not proliferate and differentiate to mature megakaryocytes in response to thrombopoietin (TPO, also termed THPO) as shown by colony-forming assays in semisolid medium (de Alarcon et al, 1991; Ballmaier et al, 1997) . This impaired reactivity toward TPO is also found in platelets that still express the TPO receptor c-Mpl (also termed MPL) on its surface (Ballmaier et al, 1998) . TPO in patients is still biologically active, and serum levels are slightly elevated (Ballmaier et al, 1997) , although they are much lower compared to CAMT patients (Cremer et al, 1999) . TPO reactivity in platelets of TAR patients over time has been used to better understand whether and how this cytokine might affect the amelioration of the low platelet count in the majority of patients. Unexpectedly, older patients show a more normal TPO responsiveness, as observed by phosphorylation of JAK2 and downstream STAT molecules . Even more puzzling remains that the shift in TPO responsiveness does not coincide with the increase in platelet counts, suggesting that these processes are unrelated to some degree.
Diagnosis/Differential diagnoses
The combined features of thrombocytopenia and skeletal malformation (shortened forearms and club hands) are readily associated with the diagnosis of TAR syndrome. However, some patients remain incorrectly diagnosed into adulthood, calling for differential diagnoses to be considered in order to reduce these cases. Even though TAR syndrome is a rare disorder, it can be misinterpreted as Fanconi Anaemia (FA) (Alter, 2007; Elmakky et al, 2015) . Although complete absence of radius bones is very rare in FA, it might occur together with low platelet counts, directing toward a wrong diagnosis. However, in those FA patients with missing radii, the thumbs are also absent, which is an important morphological difference between FA and TAR syndrome. Nonetheless, FA should be excluded by standard tests (cell cycle analysis and molecular testing of the FANC gene family, or chromosomal breakage analysis). Other disorders with similar skeletal malformations (including Robert syndrome or Holt-Oram sydrome) are not primarily associated with haematological alterations (Elmakky et al, 2015) .
Following the identification of the two SNPs, at least 22 new TAR cases have been reported (Omran et al, 2012; Bottillo et al, 2013; Baken et al, 2014; Idahosa et al, 2014; Papoulidis et al, 2014; Reid et al, 2014; Yassaee et al, 2014; Al Kaissi et al, 2015; Kumar et al, 2015a,b; Pereira et al, 2015; Tassano et al, 2015; Nicchia et al, 2016; Jameson-Lee et al, 2017) . However, the presence of the microdeletion on chromosome 1q21.1 or of the hemizygous SNPs has not been reported in more than half of the described patients (Omran et al, 2012; Baken et al, 2014; Idahosa et al, 2014; Reid et al, 2014; Al Kaissi et al, 2015; Kumar et al, 2015b; Pereira et al, 2015) . Many clinical issues of TAR syndrome remain enigmatic: How does the increase in platelet count occur prior to the shift in TPO reactivity in patients' platelets? Why do some patients encounter massive bleeding problems, while for other patients, bleeding, even in mild forms like bruising and petechiae, are not major issues? Why is the anaemia reported in some patients more profound than expected or is it a consequence of repeated bleeding episodes? And finally, why is there leucocytosis at birth in many, but not all patients? (Hall et al, 1969; Hedberg & Lipton, 1988) . To date, most of these questions are based on precise clinical observations, but have not been addressed in a systematic analysis, especially in the light of the two genetic alterations underlying TAR syndrome. In this study, we provide a detailed analysis of how the two SNPs in context with the microdeletion might affect platelet counts and other haematological parameters in a large patient cohort.
Materials and methods

Patients
A total of 38 patients with TAR syndrome presented to the Hannover Medical School, the Charit e University Hospital Berlin, the University Hospital W€ urzburg or the Kinderspital Z€ urich between 1995 and 2015 were included in the study (Table I ). All TAR patients had a reported microdeletion (Klopocki et al, 2007; Albers et al, 2012) or the microdeletion was detected by quantitative real time polymerase chain reaction (qPCR) (Klopocki et al, 2007) . The SNPs were detected by Sanger sequencing of PCR products using the following primers: 5 0 -AGCTTGACTGGCGACCTTTC and 5 0 -CCAGCCTCGTGAAGATCTAG. The genetic trait was confirmed by (co-)segregation analysis of parents, children and other family members where possible. Platelets and haemoglobin (Hb) values were derived from patient files and only one (representative) value was taken every 3 months as depicted in Figs 1 and 2. We also examined additional red blood cell values [haematocrit, red blood cell count (RBC), percentage of reticulocytes, mean corpuscular volume (MCV), mean cell haemoglobin (MCH) and mean cell haemoglobin concentration (MCHC)] for further analyses. Reported leucocyte counts were obtained daily for the first 2 weeks, and monthly thereafter until the patients were 2 years of age. The differential blood counts, where available, were additionally subjected to analysis. The data is summarised in Table II. All retrospective studies were performed in accordance to the declaration of Helsinki and with permission of the respective local ethical boards (EA2/170/05 and 52/15).
Statistical analyses
All grouped analyses were performed using GRAPHPADPRISM Version 7 (GraphPad Software, Inc., La Jolla, CA, USA) and significance was determined using either Mann-Whitney or Kruskal-Wallis non-parametric rank tests, where appropriate.
Results
SNP analysis and platelet counts
The skeletal features of TAR syndrome might be obvious enough to be already recognized during pregnancy, but mostly by ultrasound analysis (Bellver et al, 2005; Bottillo et al, 2013; Papoulidis et al, 2014; Pereira et al, 2015) . Platelet counts have been reported for patients over time, also recognizing that in most patients, low platelet counts ameliorate over the first years of life (Hall et al, 1969; Hedberg & Lipton, 1988; Fiedler et al, 2012) . To date, any correlation of platelet counts with other parameters did not result in obvious associations.
For this study, we included TAR patients with a substantiated genetic analysis (presence of the microdeletion and one are hemizygous for the intronic SNP (Table I ). In total, we identified a total of 176 platelet counts for the 38 patients that were not obtained at the initial hospital visit or when treated with platelet concentrates. No more than one value every 3 months was documented (Table II) . As shown in Fig 1, the presence of the 5 0 UTR SNP was associated with lower platelet counts, with most values remaining below the lower reference value, even in older patients. In contrast, patients with intronic SNP had higher platelet counts, even during the first months of life, which eventually reach the reference range. Of note, all patients with 5 0 UTR SNP had very low platelet counts (<80 9 10 9 /l) at birth, as originally described for TAR syndrome. Some patients with intronic SNP also had similarly low platelet counts during their first 2 months of life. However, two patients (TARS-25 and TARS-32) quickly reached almost normal levels (black symbols on y-axis, Fig 1) . For TARS-13 this was the only reported value. Remarkably, three patients with intronic SNP (TARS-1, TARS-25 and TARS-26) were not initially identified as having TAR syndrome, because they had almost normal platelet counts. In order to further quantify this observation, we calculated the median of all platelet counts for each patient and grouped them by the genetic variants. Surprisingly, we found a marked difference between the groups: Patients with 5 0 UTR SNP had a median platelet count of 57 9 10 9 /l, while patients with intronic SNP showed a count of 128 9 10 9 /l (Fig 2A) . In order to exclude that confounders had interfered with the results, we repeated the analyses with alternative groups. First, to exclude a gender effect, we grouped the same set of median platelet counts of all patients by male and female patients (Fig 2B) . We also grouped them according to the inheritance pattern of the microdeletion (Fig 2C) , which did not reveal any association. Other factors of note, such as the dominance of girls over boys as described in earlier studies (Hall et al, 1969; Greenhalgh et al, 2002; Fiedler et al, 2012) was also present in our cohort with a comparable ratio in both SNP groups (details shown in Table I ). Moreover, we examined the immature platelet fraction (IPF) in 18 patients of both groups and could not detect any SNP association (data not shown). However, younger patients had a slightly higher IPF than older patients, but remained in the same range as reported for a cohort of healthy children (Strauss et al, 2011) .
Erythropoiesis -ferritin
Anaemia has already been described for children with TAR syndrome: Hedberg and Lipton (1988) reported on a 'stresserythropoiesis' with a reduced haematocrit and increased red cell distribution width. In addition, polychromatophilia, anisocytosis, or poikilocytosis are also occasionally present (Hall et al, 1969) . HFE2 is a gene within the minimal deleted region on chromosome 1q21.1 and encodes hemojuvelin, a pivotal regulator of iron metabolism. Missense mutations in HFE2 cause juvenile hemochromatosis with an early onset iron overload (Papanikolaou et al, 2004) . Mice lacking Hfe2 in the liver (rather than in skeletal muscle) show suppression of the iron sensor hepcidin (Gkouvatsos et al, 2011) . Of note, unaffected carriers of the microdeletion that might have slightly altered red blood cell values or parameters of the iron metabolism that are not obvious when not in the centre of analysis.
We next sought to address whether and to what degree the genetic variant affects the erythroid lineage in our TAR patient cohort. Anaemia was evaluated by analysing haemoglobin (Hb) values over time (Fig 3) . In contrast to the reference values for platelets that are overall rather constant, Hb reference values differ age-dependently, especially in the first year of life (Orkin et al, 2009 ). Moreover, with entry into puberty, females have a lower Hb reference range than males. We therefore plotted values in respect to these timeand age-dependent reference values (grey lines in Fig 3) . We found that patients with intronic SNP had overall normal Hb values, whereas patients with 5 0 UTR SNP often showed Hb values below the lower reference value (open symbols in Fig 3) . Of note, Hb values were only documented for seven patients with intronic SNP during the first 5 years of life, implying that the overall haematopoiesis is less impaired in this group of TAR patients; these children have less hospital visits and thus fewer checks of their blood values. Children might have a certain, small loss of red blood cells due to micro-bleeds. In order to determine whether these low Hb values are associated with low platelet counts, we correlated these two parameters. We could not detect obvious associations between low Hb values and platelet counts (data not shown). Most of the low Hb values were documented during the first 5 years of life with no obvious bias to boys or girls, but exclusively with 5 0 UTR SNP.
These results prompted us to further study whether the reduced Hb is a consequence of impaired production or increased clearance of red blood cells, so we analysed the parameters of iron metabolism: ferritin, iron, transferrin receptor and (pro-)hepcidin. Interestingly, none of these parameters were systematically deregulated. There was no consistent pattern of repeated or prolonged bleeding episodes (i.e. petechiae or gastrointestinal bleedings) evident in the reported patient files that could explain anaemia. The data imply that TAR patients with 5 0 UTR SNP show a red blood cell production defect during their first years of life that normalizes afterwards. In contrast, all TAR patients with intronic SNP had reported Hb values within the age-dependent reference range. Of note, the number of Hb values obtained within the intronic SNP cohort was less than expected for the number of patients in this group, providing indirect evidence that these patients have less haematological complications requiring further hospital or doctor's visits that result in the documentation of blood values. Of seven patients with 5 0 UTR SNP that had extremely low Hb values during their first weeks of life, five had a documented transfusion of red blood cells, whereas there is no information on the remaining two patients. Our data suggest that bleeds are not a major contributor to low Hb in our cohort. Usually, massive bleeds are required to produce a significant reduction in Hb (Fig 3) . Hb values also normalized for patients with 5
0 UTR SNP as they aged (around 5-6 years of life), suggesting a compensatory mechanism rather than an exhaustion of a progenitor pool as found for CAMT (Ballmaier et al, 2001 ). Iron-deficient anaemia typically becomes evident for MCV values below 70 fl, as typically found in patients with microcytic iron-deficiency anaemia, but was not observed in our cohort. Only one patient (TARS-43) had microcytic red blood cells. After sufficient iron supplementation and the expected increase in platelet count to more than 40 9 10 9 /l after the age of 3 years, this patient's Hb and MCV improved. Some TAR patients had a reduced haematocrit and a slightly increased red cell distribution width, but there was not enough data available for further analysis. Reticulocytes were hardly documented in any patient. All of the documented red blood cell parameters can account for the initiation of anaemia or for an increased blood loss.
Leucocytosis and eosinophilia
Thrombocytopenia absent radii patients are reported to be born with extremely high white blood cell (WBC) count that is referred to as leucocytosis or a leukaemoid reaction, often with eosinophilia (Hall et al, 1969) . We analysed the reported WBC count daily for the first 2 weeks and then once per month, and depicted the data we collected -dependent on the underlying SNP -by age (Fig 4) . Both SNP 
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ª 2017 John Wiley & Sons Ltd groups mainly had high WBC counts that normalized after the first weeks of life. This finding suggests that leucocytosis is linked to the TAR syndrome itself (or the microdeletion) and not correlated to any SNP (as shown for platelet counts and Hb). It could be that the high WBC count during the first days of life is rather a regulatory mechanism, possibly to counteract the lack of megakaryocytic progenitors. Hb values were typically normal at this time, while platelet counts were below 60 9 10 9 /l for all patients with leucocytosis. However, there were also patients with a similar low platelet count and a normal WBC count during the first days of life, so that we cannot necessarily link the leucocytosis with alteration in the red blood cell lineage or platelets.
Non-haematological features
So far, we could not attribute any of the additional features of patients with TAR syndrome with the 5 0 UTR SNP or the intronic SNP (Table III) . However, this might be masked by the variable reporting details within the clinical files available for our retrospective analysis. Heart defects and urogenital deformities are widely reported and were also present in our cohort, hyper-or hypothyreosis are present, but poorly documented. Three patients developed Langerhans cell histiocytosis and some older patients were treated for depression. This might be due to the genetic alterations, as copy number variations of chromosome 1q21 are reported to affect neurological features or behavioural abnormalities (Brunetti-Pierri et al, 2008; Nguyen et al, 2013) . It is also possible that this is just a consequence of the reduced quality of life.
Discussion
Diagnostics
In most cases, TAR syndrome is readily recognized by the combined presence of the two eponymous features: thrombocytopenia and bilateral radius aplasia. Low platelet counts in combination with typical bleeding signs (mostly petechiae) are evident; bone marrow biopsies to confirm a hypomegakaryocytic bone marrow are typically no longer performed. Thrombocytopenia absent radii syndrome is a very rare disorder with an incidence of about 2-10 per million (Toriello, 2011) with an apparent recessive inheritance. However, our current understanding strongly implies a digenic trait that effects one null allele of RBM8A (mostly achieved by a microdeletion on chromosome 1q21) and the presence of one of two SNPs in non-coding regions of RBM8A. The 5 0 UTR SNP is present in about 70% of reported cases and has a minor allele frequency of 3%, whereas the intronic SNP accounts for about 30%. In all cases, the SNP has been inherited from one unaffected parent. In contrast, the microdeletion can also occur de novo in about 25% of cases and is otherwise inherited from the other parent. Here, we observed a bias toward a maternal inheritance (Klopocki et al, 2007) that is so far not understood. This might overlay or mask the fact that more girls are born with TAR syndrome than boys with rates ranging from 1Á6 to over 3. While the original finding of the microdeletion has been shown by array comparative genome hybridization and confirmed by fluorescence in situ hybridization of mitotic chromosomes, this can now readily be performed by qPCR analysis using a series of primer pairs located within and close to the minimal deleted region. The SNPs are typically identified by Sanger sequencing. Alternatively, next generation sequencing approaches are sensitive enough to detect both the SNP and the microdeletion by a reduced number of reads, when the relevant probes have been carefully selected to cover the non-coding 5 0 UTR and intronic SNPs (Nicchia et al, 2016; Andres et al, 2017) . The clinical features are overall specific and rather distinct, but a small series of differential diagnoses and additional non-haematological features might mask the diagnosis. Patients might present with only one absent radius bone (Kumar et al, 2015b) or have Fallot's tetralogy (Kumar et al, 2015a) . In some cases, despite thrombocytopenia in association with absent radii, other genetic conditions might lead to a similar phenotype. It is worth considering whether this should still be referred to as TAR syndrome. The trait remains complex, digenetic and should not be designated autosomal-recessive, as found in some recent review articles (e.g., Idahosa et al, 2014; Al-Qattan, 2016; Nicchia et al, 2016) . Knowledge of the underlying genetics in addition to parental segregation will allow to further substantiate the diagnosis and to discuss options for the risk of having a second child with TAR syndrome, which depends on whether the microdeletion is inherited or occurred de novo. Also, for patients with TAR syndrome, a potential partner can be tested for the presence of any SNP (with a significant likelihood for the 5 0 UTR SNP and less for the intronic SNP or the presence of the microdeletion). We have had two TAR patients that have become mothers of healthy children. Genetic counselling is thus very important for patients and for associated family members. The thrombocytopenia in TAR syndrome is due to a paucity of megakaryocytes: their number is markedly reduced in smears and the bone marrow is rather hypomegakaryoctic. This has led to TAR syndrome being considered a BMFS. However, clearly separating this syndrome from other unilineage BMFS, like Shwachman-Diamond syndrome and Diamond-Blackfan anaemia for the erythrocyte lineage or Kostmann syndrome for the neutrophil lineage, TAR syndrome is not overtly associated with a pre-malignant progression. CAMT can readily be considered as a BMFS, as the haematopoietic stem cell pool exhausts over time in the absence of a functional TPO/c-Mpl signalling axis beyond the megakaryocytic lineage (Ballmaier et al, 2001) . In our patient cohort we did not find any case of progression into leukaemia. However, there are five case reports with two paediatric cases of acute myeloid leukaemia (AML) (Rao et al, Table III . Non-haematological features of all TAR syndrome patients presented in this study. 1997; Fadoo & Naqvi, 2002) and two adult AML cases (Go & Johnston, 2003; Jameson-Lee et al, 2017) , as well as one paediatric case of acute lymphoblastic leukaemia (ALL) (Camitta & Rock, 1993) . Of note, in most patients, the diagnosis of TAR has been solely raised on the clinical appearance at that time and misdiagnoses cannot be ruled out. None of our patients had signs of BMFS or transition into myelodysplastic syndrome (MDS), especially considering older patients. Y14 is a key component of the exon junction complex and affects splicing (Kataoka et al, 2000) . Mutations in other splice factors such as U2AF1 (Graubert et al, 2012) or SF3B1 (Quesada et al, 2012) have been detected in haematological malignancies, grouped and coined as splicopathies (Hahn & Scott, 2012) . Of note, some of our patients show a continuous very low platelet count, even into the 4th decade of life. One of them suffered from a cranial haemorrhage. Unfortunately, there is no information of the reported leukaemia cases regarding the SNPs. Moreover, three of our patients have developed Langerhans cell histiocytosis, as reported for other TAR patients with reported microdeletion 1q21.1 (Giordano et al, 2011; Guastadisegni et al, 2012) . Obviously, with better treatment options, TAR patients become older and co-morbidities more overt.
Therapy
So far, there is no specific therapy for TAR syndrome. Typically the low platelet counts translate into an increased bleeding risk during the first years of life, but can decrease over time in most patients. The management of children with TAR syndrome has been described recently, but mostly with focus on skeletal features (McLaurin et al, 1999; Coccia et al, 2012) . Patients typically receive platelet transfusions during the first years of life (Hedberg & Lipton, 1988) , although this is often dependent on the treating physician or the experience of the hospital. Our retrospective data analysis clearly shows that some patients might become severely anaemic (especially patients with 5
0 UTR SNP) and should also be transfused with red blood cell concentrates. Platelet function is somewhat impaired, as described by ourselves and others (Day & Holmsen, 1972; Sultan et al, 1972; Fiedler et al, 2012) , suggesting that drugs such as nonsteroidal anti-inflammatory drugs (NSAID) should be avoided or patients monitored carefully during treatment.
Other treatments
The skeletal features vary substantially among TAR patients and in this cohort we could not detect any correlation of the severity with the presence of any SNP, as recently described (Albers et al, 2012) . The short stature is present in many patients (Greenhalgh et al, 2002) and might lead some patients to surgical means to extend the growth of the short extremities during puberty. Treatment with growth hormones hypoplasia; UH, ulna hypoplasia; PHO, phocomelia; HS, hypoplasia of the shoulder girdle; LL, lower limbs; HD, hip dysplasia; KA, knee abnormalities (GVR, genu varus; GVL, genu valgus; Con, Contracture); CHF, congenital heart failure (VSD, ventricle-septum-defect; ASD, atrium-septum-defect; PFO, patent foramen ovale; PDA, patent ductus arteriosus); UGS, anomalies of the genitourinary system (1, horseshoe kidney; 2, hypoplasia of the uterus/vagina; 3, renal pelvis dilatation; 4, renal agenesis; 5, cryptorchism; 6, funikozele); CMI, cows milk intolerance. Shown are skeletal defects of the upper (HH, TH, UH, PHO, HS) and the lower (LL, HD, KA) extremities, heart defects (CHF), urogenital deformities (UGS) and cow's milk intolerance (CMI).
has been considered in individual cases (G. Strauß, unpublished observations) . The use of second-generation thrombomimetics for those patients with excessive bleeding problems might be an option. Thrombomimetics are approved for adult patients with refractory chronic immune thrombocytopenia (ITP) and pilot studies for paediatric patients are ongoing and have the possibility to improve efficacy and safety. Of note, in children the risk of bone marrow fibrosis as a common adverse effect of these drugs is increased and they should be monitored carefully. Annual clinical observation with blood count assessment is recommended to detect alterations in any blood cell lineage on time.
Conclusions
We recently demonstrated that the impaired responsiveness of haematopoietic stem and progenitor cells as well as platelets toward TPO, as typically found in young patients with TAR syndrome, ameliorates in older patients . Patients with intronic SNP might have a reduced risk of bleeding due to the overall normal platelet counts, although some differences in platelet function might be present. So far, the mechanism of how sub-haploinsufficiency of Y14 might affect the hypomegakaryocytic phenotype in TAR syndrome is still unknown. While altered splicing or differential stability of distinct mRNA might be the cause due to a changed exon junction complex, there is also a direct link of Y14 with STAT3, a central signalling molecule downstream of TPO (Ohbayashi et al, 2008; Muromoto et al, 2009 ). The mode of action for RBM8A/Y14 thus remains enigmatic and will most likely reveal new surprises in the future for the aetiology of TAR syndrome.
